{"id":176581,"date":"2019-05-02T00:00:00","date_gmt":"2019-05-01T22:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/alemtuzumab-restriction-de-lutilisation-pour-des-raisons-de-securite\/"},"modified":"2026-04-09T17:12:09","modified_gmt":"2026-04-09T15:12:09","slug":"alemtuzumab-restriction-de-lutilisation-pour-des-raisons-de-securite","status":"publish","type":"post","link":"https:\/\/h.bcfi.be\/fr\/alemtuzumab-restriction-de-lutilisation-pour-des-raisons-de-securite\/","title":{"rendered":"Alemtuzumab &#8211; Restriction de l&rsquo;utilisation pour des raisons de s\u00e9curit\u00e9"},"content":{"rendered":"<p>Suite \u00e0 de nouveaux effets ind\u00e9sirables&#x002C; l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA) a lanc\u00e9 une r\u00e9\u00e9valuation du rapport b\u00e9n\u00e9fice\/risque d\u2019<a href='https:\/\/www.cbip.be\/fr\/chapters\/13?frag=21063'>alemtuzumab<\/a> (Lemtrada\u00ae) pour le traitement de la scl\u00e9rose en plaques. Cela concerne les effets secondaires cardiovasculaires (y compris les cas mortels) et les effets ind\u00e9sirables \u00e0 m\u00e9diation immunitaire (h\u00e9patite auto-immune et lymphohistiocytose h\u00e9mophagocytaire). Des informations suppl\u00e9mentaires sont disponibles <a href='https:\/\/www.fagg.be\/sites\/default\/files\/content\/dhpc_lemtrada_fr_-_website.pdf'>via la communication directe avec les professionnels de la sant\u00e9<\/a> (Direct Healthcare Professional Communication &#8211; DHPC).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suite \u00e0 de nouveaux effets ind\u00e9sirables&#x002C; l\u2019Agence europ\u00e9enne des m\u00e9dicaments  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,62],"tags":[20213,20224],"class_list":["post-176581","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2019-fr","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/posts\/176581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/comments?post=176581"}],"version-history":[{"count":1,"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/posts\/176581\/revisions"}],"predecessor-version":[{"id":179159,"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/posts\/176581\/revisions\/179159"}],"wp:attachment":[{"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/media?parent=176581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/categories?post=176581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/h.bcfi.be\/fr\/wp-json\/wp\/v2\/tags?post=176581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}